Neuromuscular blocking drugs in intensive care units (ICU) may cause complications, including prolonged neuromuscular block as a result of overdosage and post-ventilation muscle weakness. These may be increased by using inappropriately high infusion rates for infants, in whom published studies are scarce, and by failure to monitor neuromuscular block. There is little ICU experience of acceleromyography, which may permit more reliable monitoring. To determine appropriate vecuronium infusion rates, 12 neonates/infants (median age 4 (interquartile range (IQR) 2-5) months) and 18 children (median age 3.07 (2-10) yr) were studied. The vecuronium infusion rate was adjusted to maintain train-of-four (TOF) at 1 response using the TOFguard accelerometer. Recovery time was measured from cessation of infusion until spontaneous TOF ratio recovery of 0.7. Neonates and infants required 45 % less vecuronium (mean infusion rate 54.7 (SEM 4.23) g kg 
Neuromuscular blocking drugs facilitate tracheal intubation and mechanical ventilation. Indications for intensive care use include: maintenance of a motionless state in critically elevated intracranial pressure, tenuous surgical repairs or haemodynamic instability; reduction of oxygen consumption; severe rigidity; and to facilitate procedures [1] [2] [3] . However, significant problems are reported and there is little published research into the use of these drugs in paediatric ICU practice. The aim of this study was to determine appropriate vecuronium infusion rates in paediatric ICU and assess acceleromyography for monitoring neuromuscular block in the ICU.
Long-term use of neuromuscular blocking agents may be associated with prolonged weakness, either from prolonged neuromuscular block [4] or from a poorly characterized myopathy [1] . It occurs more commonly with aminosteroid blockers [2] but is found with benzylisoquinolinium compounds [3] . Neuromuscular block may be prolonged by drug overdose or by accumulation of active metabolites [5] . Risk factors for prolonged weakness include hypocalcaemia [6] , renal failure [7, 8] , metabolic acidosis and hypermagnesaemia [8] . Aminoglycosides prolong the action of neuromuscular blockers by inhibition of presynaptic acetylcholine release and stabilization of postjunctional membranes [9] .
Alternatively, tachyphylaxis caused by spontaneous breakdown of atracurium or alterations in protein binding, receptor sites (up-regulation) or volume of distribution may occur. In up-regulation, extrajunctional cholinergic receptor proliferation significantly increases requirements for neuromuscular blockers over time [10] . Other complications of these drugs include histamine release [11] and cardiovascular instability. Atracurium, for example, can cause hypotension and tachycardia at higher doses or on rapid administration [12] . Laudanosine, an atracurium metabolite, may cause seizures in animals [5] . These drugs are also implicated in "ICU psychosis" if ICU staff believe muscular paralysis is a calm, painless state not requiring extra analgesia/sedation [13, 14] .
One contributory factor in paediatric ICU may be lack of published research, so that inappropriately high infusion rates are used for infants, leading to overdosage, particularly when neuromuscular function is not monitored. The standard ICU regimen for vecuronium is a bolus of 0.1 g kg
91
, followed by 60-600 g kg 91 h 91 [15] , but during anaesthesia, neonates and infants need 40 % lower infusion rates than older children [16] .
Neuromuscular function is rarely well monitored in the ICU [17, 18] , thus increasing neuromuscular blocking drug and metabolite accumulation and resulting in reports of prolonged neuromuscular block [19, 20] and, it is suggested, myopathy by "overkilling" the receptors [19] . Monitoring is essential because the critically ill ICU patient has altered pharmacodynamics and pharmacokinetics for drugs, metabolic disturbances and possible drug interactions, making it impossible to predict the dose of neuromuscular blocker required. Judging trainof-four (TOF) response manually (or visually) with certainty is difficult [19, 21] and electromyography and mechanomyography are too cumbersome for routine ICU use. Acceleromyography (with the TOFguard) may be the answer but experience with this technique in the ICU is scarce [19] .
The purpose of this study was to determine if neonates/infants require lower infusion rates than older children and to assess the TOFguard accelerometer for paediatric ICU use.
Patients and methods
The study was approved by the Hospital Ethics Committee and informed consent was obtained from the parents of each child. Thirty critically ill patients who were expected to require neuromuscular blocking drugs to assist controlled ventilation were allocated to the study. Sedation was provided throughout by continuous infusion of morphine, midazolam, or both. Routine monitoring of the patients was in accordance with the practice of the unit and included electrocardiogram, direct arterial pressure and temperature measurement (core and peripheral). Arterial blood-gas and electrolyte measurements were carried out twice a day or more often if required, and adjustments made to ventilation and acid-base balance as necessary. The intensive care clinicians used their neuromuscular blocking drug of choice for intubation. The drug given and the dose were recorded.
Neuromuscular function was monitored at the ulnar or tibial nerve using the TOFguard nerve stimulator (Organon Teknika, Cambridge). This makes use of the Newtonian principle that acceleration is proportional to force. The piezoelectric ceramic wafer produces an electrical signal proportional to acceleration. The TOFguard is a compact, microprocessor-controlled, solid state, battery-powered system. It can deliver TOF measurements (supramaximal stimulation TOF 2 Hz), post-tetanic count and, during the recovery phase, TOF ratio. It can be programmed for use in the intensive care unit to monitor long-term relaxation and delivers a TOF stimulation every 5 min. The data are stored and can be played back from a memory card.
After tracheal intubation, neuromuscular block was monitored until the first TOF response (TOF 1) returned, at which time an infusion of vecuronium was started (with a concentration of 0.2-2 mg ml . The TOF guard was programmed to deliver a supramaximal TOF stimulus every 5 min. The aim was to maintain TOF at one response. The infusion rate and TOF response were reviewed hourly and if there was no response to TOF stimulation or three or more responses were present, the infusion was reduced or increased by 10 % of the original rate until one response was present. If the rate was changed then the TOF response was reviewed at 5-15-min intervals until stable at TOF 1 response. After initial demonstration by the author, the infusions were administered and controlled by the nursing staff. To determine the dose of vecuronium required for each patient and if it altered over time, a manual record was kept hourly of the vecuronium infusion rate, the cumulative dose infused, the TOF response and any other drugs given concurrently. Alterations to the infusion rate were also recorded. In addition, to determine if the time to spontaneous recovery was affected by the age of the patient, duration of infusion or other factors such as renal failure, the time from cessation of infusion to spontaneous recovery of a TOF ratio of 0.7 was recorded.
STATISTICAL ANALYSIS
Two sample Student's t test was used for parametric data (infusion rates) and Mann-Whitney U test for non-parametric data (recovery times) together with regression analysis of recovery times (Minitab PC version release 8) [22] .
Results
Thirty patients were studied. The range of clinical conditions included pneumonia (six patients), asthma (one), head injury (nine), smoke inhalation (one), bronchiolitis (one), laryngotracheitis (one) and postoperative cardiac surgery (11) . There were 12 patients aged less than 1 yr (median 4 (interquartile range (IQR) 2-5) months) and 18 children aged over 1 yr (3.07 (2-10) yr). The duration of infusions varied between 6-187 h (median 64.5 (IQR 30-81.5) h. Recovery times were available for 10 infants and 17 children (one neonate died during the study, one was transferred to another hospital and one infusion was discontinued after 6 h without the recovery time being recorded). Four patients developed renal failure requiring peritoneal dialysis during the study.
There was an age-dependent statistically significant difference in vecuronium requirements. The mean infusion rate for those less than 1 yr was 54.7 (SEM 4.23) g kg 91 h
91
, while for children over 1 yr it was 98.7 (7.07) g kg 91 h 91 with 95 % confidence interval (CI) of 24.8-63; the t test statistic was 4.7, with 28 degrees of freedom (df) and an associated P value of 0.0001 (table 1) .
There was also an age-dependent statistically significant difference in recovery times between the (table 2) . While the infusion rate for infants was lower than the sample mean, there was no apparent difference in infusion requirements for older children. None of the patients with renal failure demonstrated prolongation of recovery from the sample median. On re-analysing the data for vecuronium infusion requirements, without the four patients in renal failure, there was still an age-dependent statistically significant difference (P : 0.0007).
The regression equation for recovery times for all patients overall against duration of infusion was: recovery : 35.7;0.456 duration, with R 2 (adj) : 20.9 % and P : 0.006. This might suggest that time to spontaneous recovery of a TOF ratio 90.7 is related to the duration of infusion. However, the equation is highly influenced by the only outlier. This patient became very active shortly after the infusion of vecuronium was discontinued. When a child is very active it is difficult to obtain a TOFguard reading, even when obvious clinical signs of recovery, such as sustained headlift, are being demonstrated. Until nursing stimulation ceased and there was adequate sedation, there was no accurate TOF result. The recovery time finally obtained therefore reflected the time to finishing nursing activities rather than spontaneous recovery. If the analysis is repeated without this value, the equation becomes: recovery : 44.8 ; 0.292 duration, with R 2 (adj) : 4.9 % and P : 0.148, that is there would appear to be no significant relationship between the duration of infusion and recovery time. There was no evidence of prolonged weakness in any of the patients or of drugs such as aminoglycosides or steroids influencing the time to recovery. This study also found no evidence of an overall reduction in vecuronium requirements over time to suggest cumulation, or of an increase in requirements which might indicate tachyphylaxis. A regression analysis comparing duration of all infusions against infusion requirements showed no significant relationship. In addition, if the mean infusion rate for the first 6 h of the infusions (79.21 (SEM Figure 1 A: Percentile box plot of vecuronium infusion rates for "short" and "long" infusions. B: Percentile box plot of recovery times for short and long infusions. The box shows the difference between the quantiles; the median is indicated as a line and the whiskers show the extremes. The asterisk shows a possible outlier [22] . There was no significant difference in either dosage or recovery times. 91 for the final 6 h (ns). In addition, previous research has mainly analysed data from infusions lasting less than 48 h. In this study there were 14 patients who received infusions for less than 48 h ("short" infusions); these results may be compared with data from the 16 patients who received infusions for longer than 48 h ("long" infusions) (table 3) . There was no difference in age or weight between these two groups. Also, there was no significant difference in infusion rates between the two groups ( fig. 1A) . Recovery times varied between 15 and 105 min in the short infusion group and between 22 and 180 min in the long infusion group ( fig. 1B) (ns) . The data were re-analysed removing any outliers because of the variation in recovery times seen in both groups. Despite this re-analysis without the 105-min recovery time in the short group and without the 22-min recovery time in the long group, there was still no significant difference between them.
Discussion
In this study there was an age-dependent statistically significant difference in vecuronium requirements in the paediatric ICU. Neonates and infants required 45 % less vecuronium than older children.
The neuromuscular effects of bolus doses of vecuronium have been studied previously [23] [24] [25] [26] [27] , demonstrating an age-dependence of dose and recovery times [23, 26] . Similarly, infusion requirements during fentanyl-nitrous oxide-oxygen anaesthesia have been found to be 40 % lower for neonates/infants (62 (SD 15) g kg 91 h
91
) than for children aged 3-10 yr (154 (49) g kg 91 h
) [16] . The ED 95 of vecuronium for all patients less than 1 yr, including neonates, is 47 g kg 91 and is the product of the distribution volume and its plasma concentration [26] . Neuromuscular blocking drugs are distributed to the extracellular fluid volume which is approximately 44 % of body weight at birth, only approaching the adult value of 22 % at 1 yr of age [28] . In neonates and infants, therefore, it is concluded that during anaesthesia, neuromuscular block is reached at a lower total plasma concentration of vecuronium than in older children. The lower serum protein concentrations in neonates/infants may also indicate that lower total plasma concentrations of neuromuscular blocking drugs are needed.
There are few studies on vecuronium infusions in paediatric ICU and none comparing neonates/ infants with children. An infusion rate of 66 (37) g kg 91 h 91 is reported but in only 12 patients (mean age 35.5 months (range 3 weeks to 13.5 yr)), with no attempt to analyse by age and with infusions of only 12 h in duration [29] . Another report of four neonates, three infants and eight children unfortunately combined the results for infants and children (mean dose of 140 (SD 0.05) g kg 91 h
) to compare them with neonates (110 (0.05) g kg 91 h
) [17] , thus making comparison with studies during anaesthesia difficult. It suggested that the infusion rates were higher than those during anaesthesia because patients required a longer period of lung ventilation. It may be argued, however, that they reflect, instead, the relatively small sample size; that is, given the wide inter-individual variation in requirements seen in the present study (30.7- 
), their smaller numbers reflect the higher end of the range, rather than being a true population sample. Also, only three infusions lasted longer than 48 h, unlike the present study where 16 of 30 infusions lasted longer than 48 h. The present study confirms the findings from short infusions and bolus usage of agedependence in the vecuronium dose-response curve.
In addition, the present study showed an agedependent difference in recovery times between neonates/infants and older children, with faster recovery in the former. Others, however, have found an age-dependent prolongation of spontaneous recovery in neonates and infants, arguing that this results from their greater distribution volume [30] . This study is widely quoted to show that vecuronium has a longer duration of action in neonates/infants than in older children. Why then is the opposite the case in this present study ? The age-dependent prolongation of spontaneous recovery quoted refers to the time to full restoration of TOF 1 response. When TOF 1 response is restored, they also found that TOF ratio recovered faster in younger patients, suggesting proportionally more rapid restoration of muscle strength [30] . This age-dependence of TOF recovery has not been studied widely.
Another question addressed by this study was whether or not spontaneous recovery is affected by factors such as renal failure, as previously suggested [8, [31] [32] [33] . The four patients requiring peritoneal dialysis for renal failure did not have prolonged recovery but rather, in infants at least, needed smaller doses. Unlike previous reports, this study set out to adjust the infusion rate to maintain TOF at 1 response, as a fixed-dose infusion regimen in the presence of renal failure has been shown to lead to gradually increasing block [31] . Another study of seven patients with renal failure found prolonged neuromuscular block, lasting from 6 h to more than 7 days after termination of vecuronium [8] . However, neuromuscular function in these patients was monitored after the vecuronium infusion was discontinued. Those patients who, despite being in renal failure, did not develop prolonged block had received significantly smaller daily doses of vecuronium (median 0.29 (range 0.23-0.42) mg kg 91 ) than those who did (0.65 (0.48-2.29) mg kg 91 ) (P : 0.05). Other studies have shown that patients with chronic renal failure have increased sensitivity to the neuromuscular blocking effects of vecuronium [33] . Initially, the increased sensitivity is offset by the increase in distribution volume so induction doses should be equal to or slightly higher than for patients without renal failure. However, because of the increased sensitivity and a possible decrease in clearance, the maintenance doses need to be reduced. This study tends to confirm these findings.
It has been suggested that with time, tolerance and up-regulation of acetylcholine (ACh) receptors occurs in ICU patients receiving neuromuscular blocking drugs, leading to increased requirements [34] . Other factors leading to up-regulation include upper and lower motor neurone lesions, muscle trauma, burns, immobilization, anticonvulsants and clostridial toxins [35] . On the other hand, it is also proposed that prolonged recovery may occur with decreased infusion rates over time if accumulation of neuromuscular blocking drug or active metabolites occurs [36] . In this study duration of infusion did not appear to affect either the dose required or time to spontaneous recovery; that is, there was no apparent evidence of cumulation or ACh receptor up-regulation, provided infusions were titrated to individual patients. Longer infusions (8-12 weeks) may affect receptors differently [10] .
Another potential problem is the development of a poorly characterized myopathy after long infusions, leading to weakness. This was not seen in the present study, despite the presence of factors such as renal failure which are thought to increase its incidence. This may result from the routine use of the nerve stimulator, which made it possible to achieve precise individual dosage of drug, avoiding "overkilling" of the ACh receptor [19, 20] .
In conclusion, this study has shown that there is an age-dependent statistically significant difference in vecuronium requirements in the paediatric ICU. Maintaining the correct infusion rate revealed that neonates/infants have a faster spontaneous recovery from TOF 1 response to TOF ratio 90.7 than older children. We also showed that renal failure does not prolong recovery when patients are fully monitored, with infusion rates adjusted to maintain TOF 1 response, but suggest that requirements may need to be reduced. Acceleromyography was a convenient and reliable method for monitoring neuromuscular function in the paediatric ICU.
